Therapure Biopharma Inc. has Acquired Plasma Protein Purification Technology From Upfront Chromatography A/S

Therapure Biopharma Inc. and Upfront Chromatography A/S have announced today that they have entered into an agreement for Therapure to acquire the assets and associated business related to human plasma fractionation from Upfront.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Mississauga, ON (PRWEB) December 03, 2013

Therapure Biopharma Inc. and Upfront Chromatography A/S have announced today that they have entered into an agreement for Therapure to acquire the assets and associated business related to human plasma fractionation from Upfront.

Upfront has developed over the last 15 years, a proprietary protein purification technology, based on Expanded Bed Adsorption (EBA) chromatography which offers significant advantages over other purification technologies.

As a result of the acquisition, Therapure gains exclusive rights for the commercialization of the Upfront technology relevant to the human plasma fractionation field. Therapure will continue to develop and market this technology under the new trademark PlasmaCap EBA.

Nick Green, CEO of Therapure, commented: “The acquisition of the PlasmaCap EBA technology is an important addition to Therapure’s purification portfolio. With PlasmaCap EBA, Therapure now possesses a technology to capture therapeutic plasma proteins that is highly efficient and less damaging to the end product compared to conventional methods of fractionation. Ultimately PlasmaCap EBA allows for a more cost-effective process to manufacture plasma proteins. Therapure has established an excellent reputation as a biologics contract development and manufacturing organization (CDMO) with integrated services including plasma protein purification. The acquisition of this technology will further support Therapure’s reputation as a leader in the biologics manufacturing sector in general, and as a global leader in terms of plasma protein purification. We feel strongly that this technology can add significant value to our clients as they seek to optimize their manufacturing processes and associated economics.”

Upfront divested their pharmaceutical business unit in April 2010 to DSM Biologics, and is now focusing on their BioMine business line, where the technology is offered to the food/feed ingredients business for extraction of food grade proteins.

“We see this additional divestment of our technology to Therapure as a major milestone for Upfront,” commented Michael Pålsson, CEO of Upfront. “It is yet another significant blue-stamp of our technology, driven by its value creation in the capture of high value proteins. We are now ready to focus 100% on our BioMine business which aims to valorize under-utilized side and waste streams from the food, feed and biofuel industries. There is a broad range of food and feed industries in the world with large volumes of side and waste streams containing valuable proteins. We are able to help these manufacturers get more value out of these streams, and at the same time we see a growing, global need for alternative protein sources to feed the world’s population.”

About PlasmaCap EBA
PlasmaCap EBA is an innovative technology for cost-effective capture of plasma proteins at high yields and purities. PlasmaCap EBA uses proprietary high density resins in expanded bed adsorption (EBA) chromatography to capture plasma proteins directly from plasma or fractionated plasma materials. Through substantial development efforts, PlasmaCap EBA has been able to achieve significant capture yields for major plasma proteins of value. PlasmaCap EBA is owned by Therapure Biopharma Inc., which has developed the technology to enhance its contract manufacturing offerings for plasma fractionators, plasma protein manufacturers, and biopharma manufacturers.

Visit http://www.plasmacap.com for more information.

About Therapure Biopharma Inc.
Therapure Biopharma Inc. is an integrated biopharmaceutical company focused on complex biological therapeutics and technologies that can provide new options for patient care. It is comprised of Therapure Biomanufacturing, the award-winning CDMO division and Therapure Innovations, the proprietary drug pipeline and platform technology research and development division. Therapure Biopharma Inc.'s 130,000 sq. ft. cGMP facility includes biomanufacturing, research and quality-control laboratories and is built to meet FDA (USA), HPFB (Canada), EMA (Europe) and MHRA (UK) standards.

Visit http://www.therapurebio.com for more information.

About Upfront Chromatography
Upfront Chromatography A/S is a Danish high-tech company located in Copenhagen. Upfront Chromatography offers industrial-scale customized separation solutions to isolate and purify soluble proteins from industrial process streams.

Visit http://www.upfront-dk.com for more information.

For more information, please contact:

Nicholas Green
President and CEO
Therapure Biopharma Inc.
Tel: +1 (905) 286 6200
plasmacap(at)therapurebio(dot)com

Michael Pålsson
CEO
Upfront Chromatography A/S
Tel: +45 60 82 92 00
sales(at)upfront-dk(dot)com


Contact